Merck wins FDA approval of combo asthma therapy

The FDA has waved the green regulatory flag for Merck's new asthma drug Dulera, a two-in-one fixed-dose combo drug that is also being studied for chronic obstructive pulmonary disorder. Dulera combines mometasone furoate and formoterol fumarate, which Merck acquired in its buyout of Schering-Plough.

"Asthma control is an important treatment goal and Dulera provides a new option for physicians to help manage this chronic condition in appropriate patients," said S. Blaiss, M.D., clinical professor of pediatrics and medicine at the University of Tennessee Health Science Center. The drug was approved for use among patients 12 and older.

Dulera spurs a dual action as both an inhaled corticosteroid and a long-acting beta agonist, which has raised some safety concerns that may have slowed the agency's approval process, according to Reuters.

- read the Merck release
- here's the story from Reuters

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.